Flavivirus Infections

01/01/2012 - "While cross-reactive antibodies with therapeutic potential against flaviviruses have been generated, the majority of them are anti-E antibodies with the potential to cause antibody-dependent enhancement of flavivirus infection and disease. "
08/01/2015 - "The study thus provided important new information on the potential immunomodulatory role of preexisting antibodies in a flavivirus system that can be relevant for understanding individual-specific factors influencing antibody responses in sequential flavivirus infections and/or immunizations."
02/01/2015 - "Although there were no previous reports of flavivirus infections in BiH, described cases had high titre of WNV specific antibodies in serum, and negative flavivirus-vaccination history, they were defined as probable cases because recommended testing for case confirmation was not performed. "
06/01/2013 - "Flavivirus infection was detected by indirect immunofluorescent assay of inoculated C6/36 cells using polyclonal flavivirus antibodies (St. Louis encephalitis virus, yellow fever virus and dengue virus type 1) and confirmed by RT-PCR. "
04/01/2011 - "However, serological identification of the infecting agent in secondary or subsequent flavivirus infections is problematic due to the extensive cross-reactivity of flavivirus antibodies. "

11/01/2007 - "Development of improved vaccines against Flavivirus infections is therefore important. "
10/01/2009 - "Development of safe and effective live-virus vaccines against neurotropic flavivirus infections demands a detailed knowledge of their neuropathogenesis in a primate host that is evolutionarily close to humans. "
01/01/2009 - "The complete conservation of these immunologically relevant sequences through the entire recorded WNV history suggests they will be valuable as components of peptide-specific vaccines or other therapeutic applications, for sequence-specific diagnosis of a wide-range of Flavivirus infections, and for studies of homologous sequences among other flaviviruses."
01/01/2004 - "The development of new vaccines is of vital importance, but the stringent need for safety, efficacy and cost-effectiveness together with the problems associated with the specific immune pathogenesis of some flavivirus infections impose significant challenges to innovative vaccine research. "
01/01/2014 - "Despite the extensive research and public health concern associated with flavivirus diseases, to date, there is no specific treatment available for any flavivirus infections, though commercially available vaccines for yellow fever, Japanese encephalitis and tick-born encephalitis exist. "

01/01/1988 - "By analyzing lysates of BHK cells infected with St. Louis encephalitis virus or Powassan virus and proteins from dengue-2 virus-infected mouse brain we have demonstrated that the appearance of the high-molecular-weight form of NS1 is a general feature of flavivirus infection. "
02/20/2015 - "The results fit with our current understanding of DENV C and pep14-23 structure and function, paving the way for similar approaches to understanding disordered proteins and improved peptidomimetics drug development strategies against DENV and similar Flavivirus infections. "
01/01/2013 - "In the present study, we studied the effect of AP-1 and AP-3 deficiency on flavivirus infection in cells functionally lacking these proteins. "
05/01/1992 - "The distribution of intracellular viral RNA and proteins was coincident with the RDRP, all being located in the F4 and F5 bands which contained the characteristic membrane structures induced during flavivirus infection. "
04/01/2014 - "Complement-related proteins control the flavivirus infection of Aedes aegypti by inducing antimicrobial peptides."

03/01/1990 - "The prophylactic efficacy of the broad-spectrum antiviral nucleoside analog ribavirin against flavivirus infection in non-human primates was investigated in a blinded, placebo-controlled study of rhesus monkeys infected with dengue virus. "
02/01/2003 - "However, ribavirin did not enhance the inhibitory effect of interferon therapy in this animal model for flavivirus infections."

08/01/1994 - "Moreover, the assumption that humoral immunity induced by virus structural envelope glycoproteins is the only effective means of providing protection against flavivirus infection can be questioned. "
11/01/1993 - "It also showed that BFA could be used as a tool to understand further the trafficking of glycoprotein from the ER to Golgi in flavivirus infection in Vero cells."
08/01/1990 - "The biosynthesis of the flavivirus nonstructural glycoprotein, NS1, has important implications for (1) vaccine production, since NS1 immunity can protect animals from flavivirus infection; and (2) virion maturation, since NS1 is coretained with immature forms of the structural glycoprotein E in the endoplasmic reticulum (ER) of infected cells. "

12/01/1985 - "A significantly greater proportion of enhancing antibodies (Eab) were found in YF-immune (YFI) individuals (50%) as compared to those with no evidence of flavivirus infection (9.5%). "
01/01/1988 - "Heterologous flavivirus infection-enhancing antibodies in sera of Nigerians."

02/01/2003 - "We evaluated the prophylactic and therapeutic efficacy of interferon alpha-2b, pegylated interferon alpha-2b, poly(I. C), and Ampligen against Modoc virus encephalitis in an animal model for flavivirus infections. "
01/20/2011 - "Although the Oas/RNase L pathway was previously shown to have an antiviral role during flavivirus infections, Oas1b protein inhibited Oas1a in vitro synthetase activity in a dose-dependent manner and reduced 2-5A production in vivo in response to poly(I:C). "

02/01/2003 - "However, ribavirin did not enhance the inhibitory effect of interferon therapy in this animal model for flavivirus infections."
10/01/1988 - "Interferon-independent increases in class I major histocompatibility complex antigen expression follow flavivirus infection."
02/01/2003 - "We evaluated the prophylactic and therapeutic efficacy of interferon alpha-2b, pegylated interferon alpha-2b, poly(I. C), and Ampligen against Modoc virus encephalitis in an animal model for flavivirus infections. "

02/20/2015 - "The results fit with our current understanding of DENV C and pep14-23 structure and function, paving the way for similar approaches to understanding disordered proteins and improved peptidomimetics drug development strategies against DENV and similar Flavivirus infections. "

02/01/2003 - "We evaluated the prophylactic and therapeutic efficacy of interferon alpha-2b, pegylated interferon alpha-2b, poly(I. C), and Ampligen against Modoc virus encephalitis in an animal model for flavivirus infections. "

03/01/1980 - "[The course of flavivirus infections in mice in the presence of the graft versus host reaction under conditions of 2-way incompatibility]."

02/01/2013 - "Collectively, our data demonstrate that GRFT is an antiviral agent with potential application in the development of therapeutics against JEV or other flavivirus infections."

01/01/2015 - "The microspheres coupled to WNV.sE or rEDIIIs were assayed with about 300 equine immune sera from natural and experimental flavivirus infections and 172 nonimmune equine sera as negative controls. "

01/01/2014 - "Neuropathological microscopic features of abortions induced by Bunyavirus / or Flavivirus infections."